Influence of genetic variants on the response to long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) and combination therapies in patients with chronic obstructive pulmonary disease (COPD): a systematic review
- 1Duponte Investigación y Desarrollo S.L.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disease in which patients may differ in terms of clinical course and response to drug treatment. Genetic variability may contribute to these differences by influencing drug response and clinical outcomes. This systematic review aimed to summarize the available evidence on the association between genetic variants and clinical outcomes or treatment response in patients with COPD receiving LABA- and/or LAMA-based therapies, as well as pharmacogenetic response to combination inhalants.
Methods: A systematic search was conducted in the PubMed and Scopus databases, as well as in the gray literature, for studies published between 2015 and 2026. Studies were considered eligible if they included adults with COPD receiving LABA and/or LAMA treatment, including combination regimens, and evaluated genetic variants in relation to therapeutic response. Additionally, studies focusing on disease phenotypes rather than specific pharmacogenetic markers were also included. Study selection and data extraction were performed by two independent reviewers. Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk of Bias 2 (RoB 2) tool.
Results: A total of 51 records were identified, and eight studies were included. Genetic variants in the ADRB2, FAM13A, SUMF1, MAPK8, AZU1, CSE1L , and CCL2 genes were investigated in relation to lung function, disease severity, and treatment response. ADRB2 variants (rs1042713, rs1042714, and rs1800888) were associated with lung function and exacerbation risk, although results regarding bronchodilator treatment response were inconsistent. Regarding other genetic variants, SUMF1 rs793391 emerged as a candidate variant in patients treated with combined bronchodilators and inhaled corticosteroids (ICS). However, these findings are based on limited data and currently lack independent replication, warranting cautious interpretation. Furthermore, findings from large GWAS revealed novel candidates associated with treatment outcomes, though these results were not replicated in subsequent independent enome-Wide Association Study analyses. Due to the limited number of studies and considerable heterogeneity, no meta-analysis was performed.
Conclusion: This review highlights the latest advances in COPD pharmacogenetics by synthesizing available evidence on patient responses to bronchodilators and corticosteroids. By mapping key methodological factors, the review provides valuable insight into optimizing future research.
Systematic Review Registration: www.crd.york.ac.uk/prospero/ , identifier CRD420261392469.
Related
- Peripherally acting μ-opioid receptor antagonists for recovery of bowel function after radical cystectomy: a systematic review and meta-analysis
- Efficacy and safety of P2X3 receptor antagonists in refractory or unexplained chronic cough: an updated systematic review and meta-analysis
- The efficacy of NMDA receptor antagonists in neuropsychiatric and non-motor symptoms of Parkinson’s disease: a systematic review
- Influence of the type of facial pattern on the outcome of treatment of patients with obstructive sleep-disordered breathing with an intraoral appliance.
- Medication adherence and treatment persistence following switching from vitamin K antagonists to direct oral anticoagulants: a systematic review.
BibTeX
@article{torrecillasbaena2026influence,
title = {{Influence of genetic variants on the response to long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) and combination therapies in patients with chronic obstructive pulmonary disease (COPD): a systematic review}},
author = {Bárbara Torrecillas-Baena and Yolima Puentes-Osorio and Viviana Ramírez and Manuel Alejandro Salamanca-Miñarro and Andrea García-Alcaide and Luis S. M. Pajuelo},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1973557},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1973557/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Influence of genetic variants on the response to long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) and combination therapies in patients with chronic obstructive pulmonary disease (COPD): a systematic review
AU - Bárbara Torrecillas-Baena
AU - Yolima Puentes-Osorio
AU - Viviana Ramírez
AU - Manuel Alejandro Salamanca-Miñarro
AU - Andrea García-Alcaide
AU - Luis S. M. Pajuelo
PY - 2026
DA - 2026/10/29
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1973557
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1973557/full
AB - Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disease in which patients may differ in terms of clinical course and response to drug treatment. Genetic variability may contribute to these differences by influencing drug response and clinical outcomes. This systematic review aimed to summarize the available evidence on the association between genetic variants and clinical outcomes or treatment response in patients with COPD receiving LABA- and/or LAMA-based therapies, as well as pharmacogenetic response to combination inhalants. Methods: A systematic search was conducted in the PubMed and Scopus databases, as well as in the gray literature, for studies published between 2015 and 2026. Studies were considered eligible if they included adults with COPD receiving LABA and/or LAMA treatment, including combination regimens, and evaluated genetic variants in relation to therapeutic response. Additionally, studies focusing on disease phenotypes rather than specific pharmacogenetic markers were also included. Study selection and data extraction were performed by two independent reviewers. Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS) and Cochrane Risk of Bias 2 (RoB 2) tool. Results: A total of 51 records were identified, and eight studies were included. Genetic variants in the ADRB2, FAM13A, SUMF1, MAPK8, AZU1, CSE1L , and CCL2 genes were investigated in relation to lung function, disease severity, and treatment response. ADRB2 variants (rs1042713, rs1042714, and rs1800888) were associated with lung function and exacerbation risk, although results regarding bronchodilator treatment response were inconsistent. Regarding other genetic variants, SUMF1 rs793391 emerged as a candidate variant in patients treated with combined bronchodilators and inhaled corticosteroids (ICS). However, these findings are based on limited data and currently lack independent replication, warranting cautious interpretation. Furthermore, findings from large GWAS revealed novel candidates associated with treatment outcomes, though these results were not replicated in subsequent independent enome-Wide Association Study analyses. Due to the limited number of studies and considerable heterogeneity, no meta-analysis was performed. Conclusion: This review highlights the latest advances in COPD pharmacogenetics by synthesizing available evidence on patient responses to bronchodilators and corticosteroids. By mapping key methodological factors, the review provides valuable insight into optimizing future research. Systematic Review Registration: www.crd.york.ac.uk/prospero/ , identifier CRD420261392469.
SN - 1663-9812
ER -